Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) has dosed the first patient with its TT-301 drug candidate in a Phase 1 clinical study. TT-301 has demonstrated efficacy in preclinical models of rheumatoid arthritis, intra cerebral haemorrhage (ICH) and traumatic brain injury (TBI).
Image may be NSFW.
Clik here to view.
The Company said data from the trial are a first step in the development of TT-301 for central nervous system intravenous indications, ICH and TBI. In follow up studies, Transition plans to advance oral formulations of lead drug candidates TT-301 or TT-302 for inflammatory diseases such as rheumatoid arthritis.
Both compounds can suppress inflammatory cytokine production, reduce inflammation and improve outcomes in preclinical models of collagen-induced arthritis. Currently, Phase 1 enabling preclinical studies are being performed for oral forms of both compounds.
